Novel HER-2 Targeted Therapies in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 11

PMID 38201515

Authors

Catarina Lopes Fernandes

Diogo J Silva

Alexandra Mesquita

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor 2 (HER-2)-positive breast cancer represents 15-20% of all breast cancer subtypes and has an aggressive biological behavior with worse prognosis. The development of HER-2-targeted therapies has changed the disease's course, having a direct impact on survival rates and quality of life. Drug development of HER-2-targeting therapies is a prolific field, with numerous new therapeutic strategies showing survival benefits and gaining regulatory approval in recent years. Furthermore, the acknowledgement of the survival impact of HER-2-directed therapies on HER-2-low breast cancer has contributed even more to advances in the field. The present review aims to summarize the newly approved therapeutic strategies for HER-2-positive breast cancer and review the new and exploratory HER-2-targeted therapies currently under development.

Citing Articles

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study.

Chen Y, Qiu Y, Shen H, Yan S, Li J, Wu W BMC Womens Health. 2024; 24(1):675.

PMID: 39736653 PMC: 11687059. DOI: 10.1186/s12905-024-03526-w.

Successful treatment of enormous locally advanced breast cancer through neoadjuvant chemotherapy and surgical intervention: a case report.

Sin T, Huang J, Nie L, Mao F, Shen S, Li Y Gland Surg. 2024; 13(6):1126-1136.

PMID: 39015700 PMC: 11247592. DOI: 10.21037/gs-24-92.

Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.

Koukoutzeli C, Trapani D, Ascione L, Kotteas E, Marra A, Criscitiello C Clin Med Insights Oncol. 2024; 18:11795549241260418.

PMID: 38894701 PMC: 11185006. DOI: 10.1177/11795549241260418.

References

Zhang J, McAndrew N, Wang X, Du Y, DiCarlo B, Wang M . Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor. Breast Cancer Res. 2023; 25(1):81. PMC: 10327353. DOI: 10.1186/s13058-023-01679-4. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R . Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021; 6(1):236. PMC: 8219715. DOI: 10.1038/s41392-021-00629-w. View

Pegram M, Hamilton E, Tan A, Storniolo A, Balic K, Rosenbaum A . First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021; 20(8):1442-1453. PMC: 9398097. DOI: 10.1158/1535-7163.MCT-20-0014. View

Skidmore L, Sakamuri S, Knudsen N, Hewet A, Milutinovic S, Barkho W . ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. Mol Cancer Ther. 2020; 19(9):1833-1843. DOI: 10.1158/1535-7163.MCT-19-1004. View

Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P . ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020; 473:156-163. DOI: 10.1016/j.canlet.2019.12.037. View

Liu X, Zhang P, Li C, Song X, Liu Z, Shao W . Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China. Front Oncol. 2023; 13:1136380. PMC: 10316697. DOI: 10.3389/fonc.2023.1136380. View

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

Kang J, Sun W, Khare P, Karimi M, Wang X, Shen Y . Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nat Biotechnol. 2019; 37(5):523-526. PMC: 6668989. DOI: 10.1038/s41587-019-0073-7. View

10.

Freedman R, Gelman R, Wefel J, Melisko M, Hess K, Connolly R . Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016; 34(9):945-52. PMC: 5070554. DOI: 10.1200/JCO.2015.63.0343. View

11.

Baselga J . Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer. 2001; 37 Suppl 1:18-24. View

12.

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini P . Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010; 16(9):2688-95. PMC: 3243489. DOI: 10.1158/1078-0432.CCR-09-3407. View

13.

Huang S, Li F, Liu H, Ye P, Fan X, Yuan X . Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018; 10(6):864-875. PMC: 6152455. DOI: 10.1080/19420862.2018.1486946. View

14.

Espelin C, Leonard S, Geretti E, Wickham T, Hendriks B . Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer. Cancer Res. 2016; 76(6):1517-27. DOI: 10.1158/0008-5472.CAN-15-1518. View

15.

Goss P, Smith I, OShaughnessy J, Ejlertsen B, Kaufmann M, Boyle F . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2012; 14(1):88-96. DOI: 10.1016/S1470-2045(12)70508-9. View

16.

Bian L, Xu B, Di L, Wang T, Wang X, Jiao S . [Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]. Zhonghua Yi Xue Za Zhi. 2020; 100(30):2351-2357. DOI: 10.3760/cma.j.cn112137-20200116-00105. View

17.

Miller K, Cortes J, Hurvitz S, Krop I, Tripathy D, Verma S . HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016; 16:352. PMC: 4893300. DOI: 10.1186/s12885-016-2385-z. View

18.

Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L . Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017; 110:51-61. DOI: 10.1016/j.ejps.2017.01.021. View

19.

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J . Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-44. DOI: 10.1016/S1470-2045(11)70397-7. View

20.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View